News

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% year on year to $1.09 billion. On the other hand, the company’s full-year revenue guidance of $4.28 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $6.60 per share was 13.6% above analysts’ consensus estimates.

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.27 per share was significantly above analysts’ consensus estimates.

Sterling (NASDAQ:STRL) Reports Sales Below Analyst Estimates In Q4 Earnings

Civil infrastructure construction company Sterling Infrastructure (NASDAQ:STRL) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 2.6% year on year to $498.8 million. On the other hand, the company’s full-year revenue guidance of $2.08 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 10% above analysts’ consensus estimates.

Workiva (NYSE:WK) Posts Better-Than-Expected Sales In Q4, Stock Soars

Financial and compliance reporting software company Workiva (NYSE:WK) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 19.9% year on year to $199.9 million. The company expects next quarter’s revenue to be around $204 million, close to analysts’ estimates. Its non-GAAP profit of $0.33 per share was in line with analysts’ consensus estimates.